[
  {
    "ts": null,
    "headline": "The Score: Apple, Palantir, Intel and More Stocks That Defined the Week",
    "summary": "Tech giants rallied Wednesday after Trump announced tariff exemptions for tech companies investing in U.S. production.  The announcement came at an event trumpeting Apple’s new $100 billion investment pledge.  Apple shares jumped 5.1% Wednesday.",
    "url": "https://finnhub.io/api/news?id=49c42cfb308f54470ab4efe576f4d8f4f3d7b35afc8c13945afcbef377c50990",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754686980,
      "headline": "The Score: Apple, Palantir, Intel and More Stocks That Defined the Week",
      "id": 136276091,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Tech giants rallied Wednesday after Trump announced tariff exemptions for tech companies investing in U.S. production.  The announcement came at an event trumpeting Apple’s new $100 billion investment pledge.  Apple shares jumped 5.1% Wednesday.",
      "url": "https://finnhub.io/api/news?id=49c42cfb308f54470ab4efe576f4d8f4f3d7b35afc8c13945afcbef377c50990"
    }
  },
  {
    "ts": null,
    "headline": "Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer",
    "summary": "– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – Vepdegestrant is the first PROteolysis TArgeting Chimera (PROTAC) to demonstrate clinical benefit in patients with breast cancer – NEW HAVEN, Conn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today with its partner Pfizer Inc. (NYSE: PFE), announced that the U.S. Food and Drug Admin",
    "url": "https://finnhub.io/api/news?id=c8d7afd3cad318e005e921756e67ff1de4e039dfebea9bb23a476b8624623810",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754683500,
      "headline": "Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer",
      "id": 136273683,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – Vepdegestrant is the first PROteolysis TArgeting Chimera (PROTAC) to demonstrate clinical benefit in patients with breast cancer – NEW HAVEN, Conn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today with its partner Pfizer Inc. (NYSE: PFE), announced that the U.S. Food and Drug Admin",
      "url": "https://finnhub.io/api/news?id=c8d7afd3cad318e005e921756e67ff1de4e039dfebea9bb23a476b8624623810"
    }
  },
  {
    "ts": null,
    "headline": "EpiPen patent expiry opens new era for innovation",
    "summary": "The expiration of Viatris’s EpiPen patent in September 2025 will likely result in increased competition and lower costs in the epinephrine delivery space.",
    "url": "https://finnhub.io/api/news?id=461cdeebf40fd6ea3b8714bd3e31e95053cf3c58970b50e69ba358b71f96dd55",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754673050,
      "headline": "EpiPen patent expiry opens new era for innovation",
      "id": 136273685,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The expiration of Viatris’s EpiPen patent in September 2025 will likely result in increased competition and lower costs in the epinephrine delivery space.",
      "url": "https://finnhub.io/api/news?id=461cdeebf40fd6ea3b8714bd3e31e95053cf3c58970b50e69ba358b71f96dd55"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Trade Desk CEO Says Tariffs Impacting Key Clients; UK Regulator Approves Boeing's Acquisition of Spirit AeroSystems",
    "summary": "All three major US stock indexes were up in late-morning trading Friday and are poised to secure a w",
    "url": "https://finnhub.io/api/news?id=ad9cce6714ce0520f29a6f709cbf7620898d839ae2612a920168375e2d89ba27",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754667306,
      "headline": "Top Midday Stories: Trade Desk CEO Says Tariffs Impacting Key Clients; UK Regulator Approves Boeing's Acquisition of Spirit AeroSystems",
      "id": 136270519,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were up in late-morning trading Friday and are poised to secure a w",
      "url": "https://finnhub.io/api/news?id=ad9cce6714ce0520f29a6f709cbf7620898d839ae2612a920168375e2d89ba27"
    }
  },
  {
    "ts": null,
    "headline": "Abbott's EPD Growth Beats Market Trends: Here's How to Play the Stock",
    "summary": "Abbott outpaces market trends as EPD sales surge, fueled by double-digit growth, biosimilar approvals and strong product demand.",
    "url": "https://finnhub.io/api/news?id=81404eea55a3f2d53c7745ab8cf969aa59f2226e14b2dbfb461cb088f20d4d08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754660340,
      "headline": "Abbott's EPD Growth Beats Market Trends: Here's How to Play the Stock",
      "id": 136273688,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Abbott outpaces market trends as EPD sales surge, fueled by double-digit growth, biosimilar approvals and strong product demand.",
      "url": "https://finnhub.io/api/news?id=81404eea55a3f2d53c7745ab8cf969aa59f2226e14b2dbfb461cb088f20d4d08"
    }
  },
  {
    "ts": null,
    "headline": "Tariffs Be Damned. Stocks Flirt With a New Record High.",
    "summary": "Tariffs Be Damned. Stocks Flirt With a New Record High.",
    "url": "https://finnhub.io/api/news?id=605a210f5f4851711d50b836243607b7cde31069c371bcc16fed56f77cced7cf",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754659020,
      "headline": "Tariffs Be Damned. Stocks Flirt With a New Record High.",
      "id": 136296160,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Tariffs Be Damned. Stocks Flirt With a New Record High.",
      "url": "https://finnhub.io/api/news?id=605a210f5f4851711d50b836243607b7cde31069c371bcc16fed56f77cced7cf"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech ends patent fight with mRNA rival CureVac ahead of buyout deal",
    "summary": "The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an acquisition of its one-time COVID-19 vaccine competitor.",
    "url": "https://finnhub.io/api/news?id=fdafbf55b828db568f5f34144c6ca9dacd87d2a95a28ecc94ec96020bd082e72",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754654040,
      "headline": "BioNTech ends patent fight with mRNA rival CureVac ahead of buyout deal",
      "id": 136273690,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an acquisition of its one-time COVID-19 vaccine competitor.",
      "url": "https://finnhub.io/api/news?id=fdafbf55b828db568f5f34144c6ca9dacd87d2a95a28ecc94ec96020bd082e72"
    }
  },
  {
    "ts": null,
    "headline": "GSK to Receive $370 Million From CureVac, BioNTech Patent Dispute Settlement",
    "summary": "GSK (GSK) said Friday that it will receive $370 million from the mRNA patent settlement deal between",
    "url": "https://finnhub.io/api/news?id=633c026ef7e7ca1e0f9add8f09e920f2d5852427d3184d08ffdd2e8066ad8c96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754652770,
      "headline": "GSK to Receive $370 Million From CureVac, BioNTech Patent Dispute Settlement",
      "id": 136266922,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "GSK (GSK) said Friday that it will receive $370 million from the mRNA patent settlement deal between",
      "url": "https://finnhub.io/api/news?id=633c026ef7e7ca1e0f9add8f09e920f2d5852427d3184d08ffdd2e8066ad8c96"
    }
  },
  {
    "ts": null,
    "headline": "GSK to be paid up to £370 million after patent row settles in US",
    "summary": "CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on Thursday.",
    "url": "https://finnhub.io/api/news?id=5f4a7a1a8ef7c1a98d610201ab091059caa294551e8af11f30b453638c4e2d79",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754647942,
      "headline": "GSK to be paid up to £370 million after patent row settles in US",
      "id": 136266923,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on Thursday.",
      "url": "https://finnhub.io/api/news?id=5f4a7a1a8ef7c1a98d610201ab091059caa294551e8af11f30b453638c4e2d79"
    }
  },
  {
    "ts": null,
    "headline": "Trending tickers: Nvidia, Intel, The Trade Desk, Pinterest and GSK",
    "summary": "The latest investor updates on stocks that are trending on Friday",
    "url": "https://finnhub.io/api/news?id=72854c00e6f6d1c9c2d713cff66f2eb0e69c3b9f2257d09eec1accf38140180b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754641127,
      "headline": "Trending tickers: Nvidia, Intel, The Trade Desk, Pinterest and GSK",
      "id": 136266665,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The latest investor updates on stocks that are trending on Friday",
      "url": "https://finnhub.io/api/news?id=72854c00e6f6d1c9c2d713cff66f2eb0e69c3b9f2257d09eec1accf38140180b"
    }
  },
  {
    "ts": null,
    "headline": "GSK to Receive $370 Million in U.S. Patent Litigation Settlement",
    "summary": "The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination mRNA vaccine products made by BioNTech and Pfizer.",
    "url": "https://finnhub.io/api/news?id=0932e525196675373d445d490847f8421b434db2d33bdeeb687a1dee51fe3240",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754638260,
      "headline": "GSK to Receive $370 Million in U.S. Patent Litigation Settlement",
      "id": 136266925,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination mRNA vaccine products made by BioNTech and Pfizer.",
      "url": "https://finnhub.io/api/news?id=0932e525196675373d445d490847f8421b434db2d33bdeeb687a1dee51fe3240"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Releases Financial Results for Q2 2025",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 5, the company released its financial results for Q2 2025 and reaffirmed the 2025 revenue guidance, while increasing the guidance for adjusted diluted EPS. Pfizer Inc. (NYSE:PFE)’s strong Q2 2025 revenue and EPS performance exhibit […]",
    "url": "https://finnhub.io/api/news?id=563d858fabe962b4dba707b6e7fc3ef7d7f75b367717a664afd722f9e299debb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754624904,
      "headline": "Pfizer (PFE) Releases Financial Results for Q2 2025",
      "id": 136266926,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 5, the company released its financial results for Q2 2025 and reaffirmed the 2025 revenue guidance, while increasing the guidance for adjusted diluted EPS. Pfizer Inc. (NYSE:PFE)’s strong Q2 2025 revenue and EPS performance exhibit […]",
      "url": "https://finnhub.io/api/news?id=563d858fabe962b4dba707b6e7fc3ef7d7f75b367717a664afd722f9e299debb"
    }
  }
]